Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Double-blind Study of Rupatadine (TK-041) in Chronic Urticaria
jRCT2080222734Phase 3
- Sponsor
- Teikoku Seiyaku Co., Ltd.
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rupatadine in chronic urticaria (CU) (3 arms), sponsored by Teikoku Seiyaku Co., Ltd.
02
Drugs
rupatadine
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on jRCT2080222734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222734.